Conivaptan Yamanouchi
Doggrell, S.A.
Current Opinion in Investigational Drugs 6(3): 317-326
2005
ISSN/ISBN: 1472-4472 PMID: 15816509 Document Number: 589054
Yamanouchi is developing conivaptan, a diuretic and active vasopressin V1a and V2 antagonist, which has an aquaretic effect, for the potential treatment of hyponatremia and heart failure. In January 2004, Yamanouchi submitted an NDA in the US for injectable conivaptan for the treatment of hyponatremia and, in December 2004, the FDA issued approval, although additional safety data were requested.